Skip to main content

Table 1 Patient demographics and clinical characteristics

From: Sole adjuvant intraoperative breast radiotherapy in Taiwan: a single-center experience

  EBRT IORT p value
Age 50.02 ± 10.47 55.45 ± 10.52 0.005
 < 50 59 (47.97) 10 (21.28)  
 50–59 41 (33.33) 21 (44.68)  
 ≥ 60 23 (18.70) 16 (34.04)  
BMI 24.20 ± 3.75 25.03 ± 4.43 0.347
 ≤ 18 4 (3.25) 1 (2.13)  
 18–24 61 (49.59) 18 (38.30)  
 > 24 58 (47.15) 28 (59.57)  
Cancer type    0.210
 IDC Invasive ductal CA 114 (92.68) 39 (82.98)  
 Invasive lobular CA 3 (2.44) 3 (6.38)  
 Mucinous CA 5 (4.07) 3 (6.38)  
 Papillar CA 1 (0.81) 2 (4.26)  
pT-stage    0.188
 T1a 14 (11.38) 3 (6.38)  
 T1b 13 (10.57) 8 (17.02)  
 T1c 48 (39.02) 25 (53.19)  
 T2 47 (38.21) 11 (23.40)  
 T3–4 1 (0.81) 0 (0.00)  
Tumor size (mm)    
 Mean ± SD 17.18 ± 10.90 15.36 ± 7.41 0.216
 Median (IQR) 15 (11–22) 15 (10–19)  
 Range 1–60 1–38  
Section margin    0.161
 Negative 118 (95.93) 47 (100.00)  
 Positive 5 (4.07) 0 (0.00)  
Number of examed lymph node    0.030
 1–2 27 (21.95) 18 (38.30)  
 3–10 77 (62.60) 27 (57.45)  
 > 10 19 (15.45) 2 (4.26)  
pN-stage    0.005
 N0 95 (77.24) 47 (100.00)  
 N1 23 (18.70) 0 (0.00)  
 N2 3 (2.44) 0 (0.00)  
 N3 2 (1.63) 0 (0.00)  
ER/PR status    0.281
 Negative 20 (16.26) 11 (23.40)  
 Positive 103 (83.74) 36 (76.60)  
Her-2 status    0.194
 Negative 96 (80.67) 41 (89.13)  
 Positive 23 (19.33) 5 (10.87)  
Lymphovascular invasion    0.220
 Negative 74 (60.16) 35 (74.47)  
 Positive 45 (36.59) 11 (23.40)  
 NA 4 (3.25) 1 (2.13)  
Risk group    < 0.001
 Suitable 20 (16.26) 17 (36.17)  
 Cautionary 48 (39.02) 26 (55.32)  
 Unsuitable 55 (44.72) 4 (8.51)  
Chemotherapy    0.082
 No 40 (32.52) 22 (46.81)  
 Yes (adjuvant) 76 (61.79) 25 (53.19)  
 Yes (neoadjuvant) 7 (5.69) 0 (0.00)  
Hormone therapy    0.324
 No 23 (18.70) 12 (25.53)  
 Yes 100 (81.30) 35 (74.47)  
Target therapy    0.194
 No 110 (89.43) 45 (95.74)  
 Yes 13 (10.57) 2 (4.26)  
Follow-up time 3.67 ± 0.82 3.18 ± 0.69 < 0.001